ES2371658T3 - Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales. - Google Patents

Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales. Download PDF

Info

Publication number
ES2371658T3
ES2371658T3 ES06731937T ES06731937T ES2371658T3 ES 2371658 T3 ES2371658 T3 ES 2371658T3 ES 06731937 T ES06731937 T ES 06731937T ES 06731937 T ES06731937 T ES 06731937T ES 2371658 T3 ES2371658 T3 ES 2371658T3
Authority
ES
Spain
Prior art keywords
branched
linear
compound
prostaglandin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06731937T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2371658T3 publication Critical patent/ES2371658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06731937T 2005-04-12 2006-04-11 Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales. Expired - Lifetime ES2371658T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67023805P 2005-04-12 2005-04-12
US670238P 2005-04-12

Publications (1)

Publication Number Publication Date
ES2371658T3 true ES2371658T3 (es) 2012-01-05

Family

ID=36685683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06731937T Expired - Lifetime ES2371658T3 (es) 2005-04-12 2006-04-11 Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.

Country Status (18)

Country Link
US (1) US8962688B2 (enExample)
EP (1) EP1871380B1 (enExample)
JP (2) JP5711442B2 (enExample)
KR (2) KR101466980B1 (enExample)
CN (1) CN101198334B (enExample)
AU (1) AU2006234632B2 (enExample)
BR (1) BRPI0610557A2 (enExample)
CA (1) CA2602812C (enExample)
DK (1) DK1871380T3 (enExample)
ES (1) ES2371658T3 (enExample)
IL (1) IL186374A (enExample)
NO (1) NO20075764L (enExample)
NZ (1) NZ562763A (enExample)
PL (1) PL1871380T3 (enExample)
PT (1) PT1871380E (enExample)
RU (1) RU2468800C2 (enExample)
WO (1) WO2006109881A1 (enExample)
ZA (1) ZA200709072B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US7868045B2 (en) * 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20160015100A (ko) 2014-07-30 2016-02-12 미래파인켐 주식회사 프로스타글란딘 중간체의 제조방법
KR20170025682A (ko) 2015-08-31 2017-03-08 미래파인켐 주식회사 프로스타글란딘 유도체의 신규한 제조방법
CN107582556A (zh) * 2017-09-15 2018-01-16 成都泠汐尚品科技有限公司 一种治疗消化性溃疡的药物复方制剂
CN108051553A (zh) * 2017-12-29 2018-05-18 武汉轻工大学 一种仔猪肠道功能保护剂的筛选方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
AU2004206141A1 (en) 2003-01-24 2004-08-05 Niva Shapira Synergistic compositions and methods for potentiating anti-oxidative activity
TWI367759B (en) 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid

Also Published As

Publication number Publication date
EP1871380B1 (en) 2011-10-19
WO2006109881A1 (en) 2006-10-19
EP1871380A1 (en) 2008-01-02
NO20075764L (no) 2008-01-14
KR20140069182A (ko) 2014-06-09
CA2602812C (en) 2014-11-18
RU2468800C2 (ru) 2012-12-10
US20070276006A1 (en) 2007-11-29
RU2007141655A (ru) 2009-05-20
AU2006234632B2 (en) 2011-10-27
JP5711442B2 (ja) 2015-04-30
BRPI0610557A2 (pt) 2010-06-29
IL186374A (en) 2013-05-30
JP2013121972A (ja) 2013-06-20
IL186374A0 (en) 2008-03-20
DK1871380T3 (da) 2011-11-21
JP2008535774A (ja) 2008-09-04
KR101466980B1 (ko) 2014-12-01
ZA200709072B (en) 2008-11-26
PT1871380E (pt) 2011-11-21
PL1871380T3 (pl) 2012-03-30
CN101198334B (zh) 2013-02-06
KR20070119753A (ko) 2007-12-20
CN101198334A (zh) 2008-06-11
NZ562763A (en) 2010-12-24
US8962688B2 (en) 2015-02-24
AU2006234632A1 (en) 2006-10-19
CA2602812A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
JP5777574B2 (ja) 粘膜障害の処置のための方法および組成物
JP2013121972A (ja) 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
NO332701B1 (no) Anvendelse av bisyklisk forbindelse til fremstilling av avforingspreparat
ES2282408T3 (es) 15-ceto-prostaglandina para el tratamiento de estreñimiento por farmaco.
EP2175861B1 (en) Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1
ES2368729T3 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.
JP6408426B2 (ja) 胃腸障害処置用プロスタグランジン誘導体
CN1753680B (zh) 用于治疗腹部不适的前列腺素衍生物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
JPS6020365B2 (ja) 組成物
RU2488398C2 (ru) Фармацевтическая комбинация опиоида и простагландинового соединения
BRPI0807942A2 (pt) Agente terapêutico para distúrbio de excreção urinária
TWI594751B (zh) 治療帶有腹瀉之腸躁症之方法
RU2445961C2 (ru) Способ и композиция для лечения повреждений слизистых оболочек
RU2392941C2 (ru) Производные простагландинов для лечения желудочно-кишечного нарушения